# Sentinel (Galleri in military veterans)

Source: https://onco.cc/trials/sentinel-galleri-veterans/  
OnCo record `sentinel-galleri-veterans` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Dana-Farber study of the Galleri blood test in military veterans, a group with higher exposure to some cancer-causing hazards.

## Summary

Sentinel (NCT06523868) is a single-arm interventional study sponsored by Dana-Farber Cancer Institute with United States Department of Defense. Its primary outcomes at 12 months are positive and negative predictive value, specificity, yield and the number needed to screen.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,500 participants, a start on 31 March 2025 and primary completion expected on 30 September 2027.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: Sentinel study
- Registry id: NCT06523868
- Phase: not-applicable
- Setting: Veterans who served on active duty, screened with the Galleri test at Dana-Farber Cancer Institute with Department of Defense collaboration
- Sponsor: Dana-Farber Cancer Institute with United States Department of Defense
- Enrolled: 1500

## Sources

- ClinicalTrials.gov NCT06523868: https://clinicaltrials.gov/study/NCT06523868

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- companies: [GRAIL](https://onco.cc/companies/grail/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)

---
JSON: https://onco.cc/api/v1/entities/sentinel-galleri-veterans.json